The result of CNV gain frequency showed that URGs had higher frequencies of gain mutations in kidney chromophobe (KICH), adrenocortical carcinoma (ACC), uterine carcinosarcoma (UCS), ovarian serous cystadenocarcinoma (OV), sarcoma (SARC), and rectal adenocarcinoma (READ), whereas derlin-1 (DERL1), ubiquitin-conjugating enzyme E2W (UBE2W), peroxisomal E3 ubiquitin ligase peroxin 2 (PEX2), ubiquitin-conjugating enzyme E2C (UBE2C), PRKDC, and ubiquitin-conjugating enzyme E2V2 (UBE2V2) had higher frequencies of gain mutations across various cancer types (Fig. 1A). This evidence concerns the gene DERL1 and ovarian serous cystadenocarcinoma.